| Nov 4 |
NBIX
|
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules |
| Nov 4 |
NBIX
|
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia |
| Nov 1 |
TWI
|
Titan International Inc (TWI) Q3 2024 Earnings Call Highlights: Navigating Market Challenges ... |
| Nov 1 |
RARE
|
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? |
| Oct 31 |
TWI
|
Titan International, Inc. (TWI) Q3 2024 Earnings Call Transcript |
| Oct 31 |
NBIX
|
Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ... |
| Oct 31 |
NBIX
|
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight |
| Oct 30 |
TWI
|
Titan International (NYSE:TWI) Reports Sales Below Analyst Estimates In Q3 Earnings, Stock Drops |
| Oct 30 |
TWI
|
Titan International: Q3 Earnings Snapshot |
| Oct 30 |
TWI
|
Titan GAAP EPS of -$0.25 misses by $0.26, revenue of $447.99M misses by $23.64M |
| Oct 30 |
TWI
|
Titan International, Inc. Reports Third Quarter Financial Performance |
| Oct 30 |
NBIX
|
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript |
| Oct 30 |
GBX
|
Greenbrier Q4 rolls on higher railcar deliveries |
| Oct 30 |
NBIX
|
Neurocrine stock jumps 9% on strong Ingrezza sales, stock buyback |
| Oct 30 |
NBIX
|
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
| Oct 30 |
NBIX
|
Neurocrine Biosciences, Inc. 2024 Q3 - Results - Earnings Call Presentation |
| Oct 30 |
NBIX
|
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates |
| Oct 30 |
NBIX
|
Neurocrine: Q3 Earnings Snapshot |
| Oct 30 |
NBIX
|
Neurocrine Biosciences bats Q3 revenue estimates, revises guidance |
| Oct 30 |
NBIX
|
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance |
